- Bora Pharmaceuticals announces acquisition of Pyros Pharmaceuticals, adding VIGAFYDE to its portfolio.
Bora Pharmaceuticals Co., Ltd. has announced its acquisition of U.S.-based Pyros Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare disease treatments. Pyros, founded in 2017, recently launched VIGAFYDE, the first ready-to-use vigabatrin oral solution for infantile spasms (IS) in children aged 1 month to 2 years.
The acquisition allows Bora to expand its U.S. portfolio, following its earlier purchases of Upsher-Smith Laboratories and TWi Pharmaceuticals. VIGAFYDE, approved by the FDA in June 2024, is the only new therapy for infantile spasms approved in 15 years and offers a premixed oral solution for simplified dosing. Pyros and Bora anticipate that this partnership will better support patient needs in the rare disease space.
Bobby Sheng, Chairman and CEO of Bora, noted the strategic fit: “We see incredible synergies between Upsher-Smith and Pyros. Pyros’ innovative R&D, paired with Upsher-Smith’s established reputation in pediatric CNS, creates a powerful alliance that will enhance patient outcomes with vigabatrin.”
Michael Smith, CEO of Pyros, expressed optimism, stating, “We are excited to reach this agreement with Bora, a company that shares our commitment to rare disease support and aligns with our mission to elevate care standards.”
Both companies intend to promote VIGAFYDE and educate healthcare providers on its benefits. Vigabatrin products, including VIGAFYDE, require patient and provider enrollment in the FDA-mandated Vigabatrin REMS, ensuring informed decision-making in treatment use.
